Clearside Biomedical

Clearside Biomedical PP&E per Employee

Delisted

The PP&E per Employee of Clearside Biomedical (CLSD) as of Nov 19, 2026 is 115,818.18 USD. In the previous year, PP&E per Employee was 117,121.21 USD — a change of -1.11% (lower).

PP&E per Employee

115,818.18USD

YoY

-1.11%

Last updated:

PP&E per Employee of Clearside Biomedical is 2024 115,818.18 USD. PP&E per Employee of Clearside Biomedical was 2023 117,121.21 USD. It decreases by -1.11% lower compared to the previous year.

The Clearside Biomedical PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2017
26,969.70 USD
Jan 1, 2018
23,939.39 USD
Jan 1, 2019
36,363.64 USD
Jan 1, 2020
28,484.85 USD
Jan 1, 2021
18,484.85 USD
Jan 1, 2022
56,666.67 USD
Jan 1, 2023
117,121.21 USD
Jan 1, 2024
115,818.18 USD
The Clearside Biomedical PP&E per Employee history
YEARPP&E per EmployeeYoY
115,818.18USD-1.11%
117,121.21USD+106.68%
56,666.67USD+206.56%
18,484.85USD-35.11%
28,484.85USD-21.67%
36,363.64USD+51.90%
23,939.39USD-11.24%
26,969.70USD+888.89%
2,727.27USD-43.75%
4,848.48USD-23.81%
6,363.64USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

PP&E per Employee of Clearside Biomedical is 115,818.18 USD in 2024.

PP&E per Employee of Clearside Biomedical changed from 117,121.21 USD to 115,818.18 USD, representing a -1.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Clearside Biomedical

All Key Metrics — Clearside Biomedical